Exenatide
The first GLP-1 receptor agonist, originally derived from Gila monster venom, FDA-approved for type 2 diabetes.
Always consult a qualified clinician
This information is for educational purposes. Peptide therapy should be guided by a licensed healthcare provider. Connect with a Noho clinician
What is Exenatide?
Exenatide was the first GLP-1 receptor agonist approved for clinical use. It is a synthetic version of exendin-4, a peptide discovered in the saliva of the Gila monster lizard. It shares 53% homology with human GLP-1 but is resistant to DPP-4 degradation. Available as twice-daily (Byetta) or once-weekly (Bydureon) formulations.
Why People Talk About It
Type 2 diabetes management
StrongModest weight loss
ModerateHistorical significance as first GLP-1 drug
StrongHow It Works
Exenatide works like the body's natural GLP-1 hormone but lasts much longer because it comes from a lizard peptide that resists breakdown. It helps control blood sugar and reduces appetite.
Common Questions
Safety Information
Common Side Effects
Cautions
- • Thyroid C-cell tumor warning
- • Pancreatitis risk
- • Not for type 1 diabetes
- • Renal dose adjustment needed
What We Don't Know
Well-characterized with 15+ years of clinical use.
Published Research
33 studiesThe effect of GLP-1 receptor agonists on cognition in nondiabetic patients with mild cognitive impairment or alzheimer's disease: a meta-analysis of randomized controlled trials
Pharmacological interventions for addressing pediatric and adolescent obesity: A systematic review and network meta-analysis
Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis
Sex Differences in the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists for Weight Reduction: A Systematic Review and Meta-Analysis
Assessing the shadows: A meta-analysis of GLP-1 agonists and suicidal ideation
Quantitative analysis of the efficacy characteristics and influencing factors of weight loss drugs in children and adolescents
Efficacy, Safety, and Future of GLP-1 Receptor Agonists: A Systematic Literature Review and Meta-Analysis
Anti-obesity pharmacological agents for polycystic ovary syndrome: A systematic review and meta-analysis to inform the 2023 international evidence-based guideline
Glucagon-like peptide-1 receptor agonists in adolescents with overweight or obesity with or without type 2 diabetes multimorbidity-a systematic review and network meta-analysis
Efficacy of Glucagon-like Peptide-1 Receptor Agonists in Overweight/Obese and/or T2DM Adolescents: A Meta-analysis Based on Randomized Controlled Trials
Long-term effects of different hypoglycemic drugs on carotid intima-media thickness progression: a systematic review and network meta-analysis
Comparative effectiveness of multiple different treatment regimens for nonalcoholic fatty liver disease with type 2 diabetes mellitus: a systematic review and Bayesian network meta-analysis of randomised controlled trials
The Effectiveness and Safety of Exenatide Versus Metformin in Patients with Polycystic Ovary Syndrome: A Meta-Analysis of Randomized Controlled Trials
Comparison of exenatide alone or combined with metformin versus metformin in the treatment of polycystic ovaries: a systematic review and meta-analysis
Mitochondrial metabolites predict adverse cardiovascular events in individuals with diabetes
The Antiobesity Effect and Safety of GLP-1 Receptor Agonist in Overweight/Obese Patients Without Diabetes: A Systematic Review and Meta-Analysis
Comparative efficacy and safety of glucose-lowering drugs in children and adolescents with type 2 diabetes: A systematic review and network meta-analysis
Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta-analysis
GLP-1 receptor agonists for Parkinson's disease
Effects of exenatide long-acting release on cardiovascular events and mortality in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis
Predictors of response to glucagon-like peptide-1 receptor agonists: a meta-analysis and systematic review of randomized controlled trials
Exenatide in obese or overweight patients without diabetes: A systematic review and meta-analyses of randomized controlled trials
Once weekly exenatide: efficacy, tolerability and place in therapy
Exenatide once weekly for the treatment of type 2 diabetes: effectiveness and tolerability in patient subpopulations
Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes
The efficacy and tolerability of exenatide in comparison to placebo; a systematic review and meta-analysis of randomized clinical trials
Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials
A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes
A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus
Exenatide efficacy and safety: a systematic review
Cardiovascular outcomes with exenatide in type 2 diabetes according to ejection fraction: The EXSCEL trial
Efficacy and Tolerability of Exenatide Once Weekly Over 6 Years in Patients with Type 2 Diabetes: An Uncontrolled Open-Label Extension of the DURATION-1 Study
Always consult a qualified clinician
This information is for educational purposes. Peptide therapy should be guided by a licensed healthcare provider. Connect with a Noho clinician
Research Insights
Related Peptides
Semaglutide
StrongBeginnerA GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management, one of the most widely prescribed peptide drugs.
Liraglutide
StrongBeginnerA GLP-1 receptor agonist FDA-approved for diabetes (Victoza) and weight management (Saxenda), the predecessor to semaglutide.
Quick Facts
- Class
- GLP-1 Receptor Agonist
- Evidence
- Strong
- Safety
- Well-Studied
- Updated
- Mar 2026
- Citations
- 33PubMed
Also known as
Tags
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.
Interested in this peptide? A Noho clinician can help determine if it's right for you.
Talk to a Clinician